MBX Biosciences’ Canvuparatide Shows Promising Phase II Results in Hypoparathyroidism

MBX Biosciences reported positive Phase II data from its Avail trial for once-weekly canvuparatide in hypoparathyroidism, with 63% of patients meeting the primary composite endpoint. This included maintaining normal albumin-adjusted serum calcium levels while remaining independent of conventional therapy, active vitamin D, and high-dose calcium supplements. In the placebo group, only 31% achieved this outcome. The six-month open-label extension (OLE) further supported efficacy, with 79% of patients maintaining responder status, including those initially on placebo. The therapy was generally well-tolerated, with mild-to-moderate adverse events and no drug-related discontinuations. All 64 participants completed the 12-week study, and 94% joined the OLE. MBX plans a Phase III trial in 2026. If successful, canvuparatide could offer a once-weekly treatment that stabilizes calcium levels and reduces daily therapy burden, addressing the significant unmet needs in the hypoparathyroidism patient community.

28-11-2025